Drugs / NC410
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05572684 | Oct 2022 → Jul 2025 overdue | cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer +4 | NextCure, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04408599 | Jun 2020 → Jul 2023 | colorectal cancer, gastric cancer, ovarian cancer | NextCure, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06941857 | Sep 2025 → Dec 2028 expected | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NC410 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06941857 ↗ |
| Known as | Lair-2 igg1 fc fusion protein | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315032 ↗ |
| Modality | Monoclonal antibody | “experimental antibody drug” NCT04408599 ↗ |
| Route | Intravenous | “for IV infusion” NCT04408599 ↗ |